The CEO of Insilico Medicine, which recently became the first company to launch Phase II trials for a drug developed using generative AI, spoke with BioSpace about the rise of the technology.
The CEO of Insilico Medicine, which recently became the first company to launch Phase II trials for a drug developed using generative AI, spoke with BioSpace about the rise of the technology.